





























































Incretin action and effect of the incretin preparation for glucose metabolism in dogs. 
Hitomi Oda 
 
Incretin was shown to exert their insulinotropic effects through a variety of 
mechanisms, including increasing the rates of insulin synthesis, granule docking, and 
exocytosis. In the presence of matched glucose concentrations, insulin secretion is 
greater following ingestion of glucose than following infusion of glucose. This was 
referred to as "the incretin effect" and is believed to be modulated at least in part by 
intestinally secreted hormones such as glucose-dependent insulinotropic peptide (GIP) 
and glucagon like peptide-1 (GLP-1). Therefore, the aims of this study were to 
investigate the effect of incretin for glucose and insulin metabolism in dogs. 
In order to confirm whether dog also have “the incretin effect”, we performed the oral 
glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT) under 
similar blood glucose variation using artificial pancreas apparatus. No significant 
difference was observed in temporal serum glucose concentrations between OGTT and 
IVGTT, since we adjust the intravenous glucose infusion to reproduce similar blood 
glucose variation as the OGTT. However, insulin, GIP and GLP-1 concentration in 
OGTT were significantly higher than those in IVGTT. 
GIP produced by K-cells have commonly identified in the upper small intestine, 
whereas GLP-1 is produced by the L-cells primarily located in the distal small intestine 
and colon in human study. Therefore, the aim of this study was to examine distribution 
of tissue genetic expressions of GIP and GLP-1 in dogs. GIP genetic expression was 
highest in the duodenum as compared to other small intestine (jejunum, ileum). 
However, genetic expression of GLP-1 was the highest in ileum as compared to 
duodenum and jejunum. This result was not consistent with other mammals.  
In order to determine changes in incretin secretion with different nutritional 
composition, different diets were fed in 5 healthy dogs. GLP-1 concentration was 
significantly increased in high-fiber diet. Meanwhile, GIP secretion was increased in 
high-fat diet and decreased in high-fiber diet. 
In order to determine the effect of incretin preparations on serum glucose and insulin 
concentrations, dipeptidyl peptidase-4 (DPP-4) resistant GLP-1 analog, liraglutide was 
administered in 5 healthy dogs. Liraglutide was dispensed medication before starting 
OGTT. Significant decrease was observed in temporal serum glucose concentrations in 
liraglutide group as compared to control group. Since these dogs are healthy, insulin 
regulation is properly functioning and regulated. Therefore only a minimal amount of 
additional insulin was likely secreted, since it was not required. Insulin stimulation and 
glucagon inhibition contribute equally for the effect of GLP-1 in human study. 
Furthermore, it is known that liraglutide is capable of increasing insulin secretion and 
suppressing prandial glucagon secretion in a glucose-dependent manner. Hence, we 
speculate that stabilized glucose concentrations, after the OGTT, due to liraglutide 
treatment, may have been principally attributed to reduced glucagon secretion, instead 
of insulin secretion in healthy animals. Liraglutide's prandial glucagon suppressive 
ability appears to play a key role in its glucose-lowering effect. Since a liraglutide 
associated glucose lowering effect was observed in healthy dogs, and we suspect that 
this was principally resulting from liraglutide’s ability to suppress prandial glucagon 
release into the blood, we tested whether T1DM dogs would respond favorably to 
liraglutide treatment. T1DM dogs responded favorably to liraglutide treatment, which 
lead to a significant reduction of 46.0% in glucose AUC0-12h (total area under the 
curve for 0-12h), and a significant reduction of 66.5% in serum glucose as compared to 
baseline controls (insulin treatment only).  
This study demonstrated that healthy dogs have the incretin effect and the incretin 
secretion was affected by different nutritional composition. Moreover, incretin 
preparations affect glucose and insulin metabolism in healthy and diabetes dogs. 
 
